AND logic nanoparticle for precision immunotherapy of metastatic cancers
Source abstract
Abstract
Abstract Success in systemic immunotherapy against metastatic cancer hinges on the ability to achieve tumour-specific immune activation over normal tissues. Single-gate stimuli-responsive systems are not adequate at differentiating tumour versus normal tissue signals. Here we report an AND-gated nanoparticle that requires acidic pH and hypoxia signals to activate the stimulator of interferon genes (STING) pathway in systemic therapy of metastatic cancers. The dual stimuli-responsive nanoparticle consists of a small-molecule STING agonist conjugated to a pH-sensitive polymer through a hypoxia-sensitive linker. Biochemical analyses confirmed the (pH–hypoxia) AND logic truth table in STING activation. The nanoparticle agonist significantly reduced metastatic burdens in multiple immune-cold tumour models while exhibiting minimal systemic toxicity. Mechanistic investigation revealed that STING activation in tumour-resident type I dendritic cells drives CD8 + T cell priming and infiltration, which synergizes with immune checkpoint inhibitors. This AND logic nanoplatform offers a safe and efficacious therapeutic for STING-mediated immunotherapy against metastatic cancers.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564–1579 (2023).10.1016/j.cell.2023.03.003 ↗
2. Gupta, G. P. & Massagué, J. Cancer metastasis: building a framework. Cell 127, 679–695 (2006).10.1016/j.cell.2006.11.001 ↗
3. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Morris, V. L. & Groom, A. C. Clinical targets for anti-metastasis therapy. Adv. Cancer Res. 79, 91–121 (2000).10.1016/S0065-230X(00)79003-8 ↗
4. Weber, G. F. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 328, 207–211 (2013).10.1016/j.canlet.2012.09.025 ↗
5. Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).10.1038/s41586-019-1593-5 ↗
6. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).10.1038/nri3921 ↗
7. Flood, B. A., Higgs, E. F., Li, S. Y., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).10.1111/imr.12765 ↗
8. Jneid, B. et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci. Immunol. 8, eabn6612 (2023).10.1126/sciimmunol.abn6612 ↗
9. Marcus, A. et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49, 754–763 (2018).10.1016/j.immuni.2018.09.016 ↗
10. Wang, J. et al. STING licensing of type I dendritic cells potentiates antitumor immunity. Sci. Immunol. 9, eadj3945 (2024).10.1126/sciimmunol.adj3945 ↗
11. Harrington, K. J. et al. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann. Oncol. 29, viii712 (2018).10.1093/annonc/mdy424.015 ↗
12. Meric-Bernstam, F. et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin. Cancer Res. 28, 677–688 (2022).10.1158/1078-0432.CCR-21-1963 ↗
13. Xue, Y. et al. Stimulus-cleavable chemistry in the field of controlled drug delivery. Chem. Soc. Rev. 50, 4872–4931 (2021).10.1039/D0CS01061H ↗
14. Wang, X. H., Wang, X. Y., Jin, S. X., Muhammad, N. & Guo, Z. J. Stimuli-responsive therapeutic metallodrugs. Chem. Rev. 119, 1138–1192 (2019).10.1021/acs.chemrev.8b00209 ↗
15. Cao, Z. L., Zuo, X. L., Liu, X. C., Xu, G. X. & Yong, K. T. Recent progress in stimuli-responsive polymeric micelles for targeted delivery of functional nanoparticles. Adv. Colloid Interface Sci. 330, 103206 (2024).10.1016/j.cis.2024.103206 ↗
16. Tsuchikama, K. & An, Z. Q. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9, 33–46 (2018).10.1007/s13238-016-0323-0 ↗
17. Weiss, F., Lauffenburger, D. & Friedl, P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat. Rev. Cancer 22, 157–173 (2022).10.1038/s41568-021-00427-0 ↗
18. Altorki, N. K. et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer 19, 9–31 (2019).10.1038/s41568-018-0081-9 ↗
19. Colinge, J. -P. (ed.) FinFETs and Other Multi-Gate Transistors. Integrated Circuits and Systems 1–339 (Springer, 2008).10.1007/978-0-387-71752-4 ↗
20. Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).10.1126/science.aba1624 ↗
21. Wang, X. et al. Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window. Nat. Commun. 11, 5828 (2020).10.1038/s41467-020-19651-7 ↗
22. Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).10.1126/science.aba6098 ↗
23. Bae, Y., Fukushima, S., Harada, A. & Kataoka, K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 42, 4640–4643 (2003).10.1002/anie.200250653 ↗
24. Saito, G., Swanson, J. A. & Lee, K. D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55, 199–215 (2003).10.1016/S0169-409X(02)00179-5 ↗
25. Oh, E. T. et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nat. Commun. 7, 13593 (2016).10.1038/ncomms13593 ↗
26. Siegel, D. et al. Redox modulation of NQO1. PLoS ONE 13, e0190717 (2018).10.1371/journal.pone.0190717 ↗
27. Ding, Y. M., Dai, Y. J., Wu, M. Q. & Li, L. L. Glutathione-mediated nanomedicines for cancer diagnosis and therapy. Chem. Eng J. 426, 3489–3501 (2021).10.1016/j.cej.2021.128880 ↗
28. Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806–818 (2013).10.1016/j.immuni.2013.10.010 ↗
29. Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).10.1126/sciimmunol.aau6085 ↗
30. Dosta, P. et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat. Nanotechnol. 18, 1351–1363 (2023).10.1038/s41565-023-01447-7 ↗
31. Guisán-Ceinos, S. et al. Turn-on fluorescent biosensors for imaging hypoxia-like conditions in living cells. J. Am. Chem. Soc. 144, 8185–8193 (2022).10.1021/jacs.2c01197 ↗
32. Lemos, H. et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 76, 2076–2081 (2016).10.1158/0008-5472.CAN-15-1456 ↗
33. Fabian, K. P., Padget, M. R., Fujii, R., Schlom, J. & Hodge, J. W. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J. Immunother. Cancer 9, e001691 (2021).10.1136/jitc-2020-001691 ↗
34. Yu, J. W. et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE 13, e0206223 (2018).10.1371/journal.pone.0206223 ↗
35. Hu, J. et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature 616, 806–813 (2023).10.1038/s41586-023-05880-5 ↗
36. Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).10.1038/nature25432 ↗
37. Chen, Q. et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533, 493–498 (2016).10.1038/nature18268 ↗
38. Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).10.1038/s41467-017-00573-w ↗
39. Sivick, K. E. et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 25, 3074–3085.e5 (2018).10.1016/j.celrep.2018.11.047 ↗
40. Dane, E. L. et al. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat. Mater. 21, 710–720 (2022).10.1038/s41563-022-01251-z ↗
41. Yang, K. et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat. Nanotechnol. 17, 1322–1331 (2022).10.1038/s41565-022-01225-x ↗
42. Sivakumar, A. et al. AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity. Nat. Nanotechnol. 20, 441–450 (2025).10.1038/s41565-024-01834-8 ↗
43. Li, S. X. et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng 5, 455–466 (2021).10.1038/s41551-020-00675-9 ↗
44. Kimmel, B. R. et al. Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. Nat. Biomed. Eng 9, 1719–1739 (2025).10.1038/s41551-025-01400-0 ↗
45. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).10.1016/j.cell.2011.02.013 ↗